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698Background: Vulvar squamous cell carcinomas (SCCs) arising in association with vulvar lichen planus (LP)
are poorly documented.Objectives: We sought to present clinicopathological features of 38 patients (median age 61 years, range
39-90 years) with LP-associated vulvar SCCs.Methods: Evaluated were location of vulvar SCC and metastases at presentation, recurrences, survival,
precursor lesions, presence of human papillomavirus DNA, p16ink4a, and p53 expression.Results: In all, 32 solitary (5 pT1a, 20 pT1b, 7 pT2) and 6 multifocal SCCs, located in the vestibulum
(n = 20) and in nonhair-bearing modified and glycogenated mucosa (n = 18), arose in erosive (n = 13)
and nonerosive (n = 25) LP. All SCCs were human papillomavirus DNA and p16ink4a negative. Sixteen
of 38 (42%) women had inguinal metastases at presentation. Treatment was surgery with clear margins
(36/38) and chemoradiation (2/38). Fourteen of 36 (39%) surgically treated patients developed between 1
and 5 new SCCs in the residual diseased mucosa. Of all recurrences, 68% developed within 12 months
via precursors revealing various histologic features including elongated, but also flat rete ridges, basaloid
and hypertrophic differentiation with inconsistent p53 expression. Fourteen of 38 (37%) patients died
of SCCs.Limitations: Retrospective study and lack of a standardized treatment protocols are limitations.Conclusion: LP-associated SCCs were located in nonhair-bearing vulvar mucosa. Patients had a high rate
of inguinal metastases, recurrent vulvar cancers in diseased mucosa, and disease-related death. ( J Am Acad
Dermatol 2014;71:698-707.)
Key words: differentiated vulvar intraepithelial neoplasia; human papillomavirusenegative vulvar
carcinoma; precursor lesions; vulvar dermatosis; vulvar squamous cell carcinoma.Abbreviations used:
d-VIN: differentiated vulvar intraepithelial
neoplasia
HPV: human papillomavirus
LP: lichen planus
SCC: squamous cell carcinomaL
ichen planus (LP) is a chronic inflammatory
autoimmune dermatosis with a prevalence of
1% to 2% in the general population. LP may
involve extragenital and genital skin along with
mucosal surfaces. In the vulva, presentation of
LP depends on site of involvement. In vulvar
hair-bearing skin of mons pubis and labia majora,
and modified mucosa of interlabial sulci, labia
minora, clitoris, and perineum, LP is characterized
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Regauer, Reich, and Eberz 699and vagina, often referred to as ‘‘lichen ruber
planus.’’1,2 The risk of a patient developing a
squamous cell carcinoma (SCC) depends on the
site of involvement of LP. Although LP in extragenital
skin has no cancer risk, a 5% risk has been described
in oral and esophageal mucosa.3 Recently, LP has
been recognized as an associated condition in hu-CAPSULE SUMMARY
d Lichen planus (LP) in oral and
esophageal mucosa has a cancer risk of
up to 5%, and LP is recognized as a risk
factor for penile human papillomaviruse
negative cancer. The association of
vulvar LP and cancer, however, is poorly
documented.
d Vulvar LP-associated human
papillomavirusenegative squamous cell
carcinomas are located in nonhairy
vulvar mucosa, particularly in the
vestibulum, have a high percentage of
inguinal metastases at presentation, and
have a high rate of recurrent cancer in
residual diseased mucosa.
d The high risk for squamous cell
carcinoma in vulvar mucosal LP suggests
the need for regular and close
monitoring.man papillomavirus (HPV)-
negative penile SCCs.4,5 In
contrast, although the associ-
ation of vulvar LP and SCC
was reported as early as
1989,6 the association of
vulvar SCC with LP is poorly
documented with either case
reports only or brief mention
in larger series dealing with
diagnoses and treatment of
vulvar LP.1,7-12 Only 1 larger
series reported the associa-
tion of LP in 5 of 23
anogenital SCCs.13 The risk
for cancer in vulvar LP is
unknown, as are the typical
sites of involvement, the
type of precursor lesions,
and clinical characteristics of
LP-associated SCC.
Vulvar SCCs can be
divided according to cause
into cancers induced by HPV
and those arising indepen-
dently of HPV14 through precursor lesions called
‘‘differentiated vulvar intraepithelial neoplasia’’
(d-VIN),14,15 originally described as ‘‘differentiated
simplex in situ SCC.’’16 The origin of HPV-negative
SCCs is unclear, although mutations in the p53 gene
have been suggested17,18 and the association of
HPV-negative SCC with lichen sclerosus, a common
vulvar dermatosis with a prevalence of up to 8% in
gynecologic practices,19 is well accepted. The aim of
this article is to document clinical and histologic
features of a large series of vulvar SCCs arising in the
background of LP to elucidate possible LP-specific
characteristics.
METHODS
In all, 38 patients with a primary LP-associated
vulvar SCC were treated at the Department of
Gynecology at the Medical University Graz, Austria,
during the past 12 years. All cancers were
classified according to the seventh edition of TNM
classification of malignant tumors20: pT1a SCCs are
tumors 2 cm or less in greatest diameter and with
stromal invasion no greater than 1.0 mm; pT1b SCCare tumors greater 2 cm in greatest diameter or with
stromal invasion greater than 1.0 mm; pT2 SCCs are
tumors of any size with extension to adjacent
structures (lower third urethra, lower third vagina,
anus); and pT3 SCCs are tumors of any size with
extension to the following structures: upper two
thirds of urethra, upper two thirds of vagina, bladdermucosa, rectal mucosa, or
fixed to pubic bone. Entry
criteria were an unequivocal
(clinical and histologic) diag-
nosis of LP and a minimum
follow-up of 12 months, un-
less the end point death or
recurrence occurred earlier.
LP was divided into erosive
and nonerosive forms, and
extent of vulvar scarring was
reported.1 LP was diagnosed
clinically and confirmed
histologically, following pub-
lished criteria.21 Formalin-
fixed and paraffin-embedded
archival tissues from the
Institute of Pathology at the
Medical University Graz,
Austria, were evaluated
for HPV DNA (INNO-LiPA
HPV Genotyping Extra,
Innogenetics Diagnostic,
Heiden, Germany). All pri-
mary and recurrent invasiveSCCs and precursors were evaluated by immunohis-
tochemistry with monoclonal antibody to p53 (clone
DO-7; DAKO, Corp, Capinteria, CA) and p16ink4a
(Roche Diagnostics, Indianapolis, IN, formerly MTM
Laboratories, Heidelberg, Germany), an indirect
marker for a transforming infection with HPV
high-risk genotypes. Institutional ethics committee
approval and research study approval for this
study was obtained (Medical University, EK number
20-255ex 08/09). All patients gave consent to
photographic documentation.
RESULTS
I Clinical characteristics of primary
LP-associated SCC
See Table I. In all, 38 women (median age 61 years
at diagnosis; range 39-90 years; 9 premenopausal
and 29 postmenopausal) with a primary vulvar SCC
arising in nonerosive vulvar LP (n = 25) (Fig 1, A to
H ) and erosive LP (n = 13) were evaluated.
The nonerosive form of LP presented either as
skin-colored or white, individual or multiple papules
(n = 13) (Fig 1, A and C to F ) or larger, partly
Table I. Lichen planuseassociated vulvar squamous cell carcinomas
Patient; age
at diagnosis
Clinical type
of LP
TNM
classification
size of SCC
Localization of
first SCC
TNM
classification
lymph node
met at first
diagnosis
TNM
classification
distant mets
at first
diagnosis
First treatment
other than
surgery
First
recurrence
in months
Second
recurrence
in months
Third
recurrence
in months
Fourth
recurrence
in months
Fifth
recurrence
in months
Survival
in months
1; 39 y Papules pT1a Between clitoris
and urethra
(Fig 1, D, and
Fig 2, A and B)
pN0 (sn) Alive; 18 mo
2; 39 y Papules pT1b Clitoral hood
(Fig 1, A)
pN0 (sn) Alive; 48 mo
3; 40 y Hypertrophic pT1b (m2) Periclitoral,
labium minus
pN1a (sn) Chemoradiation 25 mo SCC pT1a 12 mo SCC
pT1b
17 mo
d-VIN
Alive; 51 mo
4; 44 y Hypertrophic pT1b (m2) Periclitoral
hymenal ring
pN0 7 mo pT1b Alive; 120 mo
5; 45 y Hypertrophic pT1b Labium minus pN0 (sn) Alive; 49 mo
6; 46 y Papules pT1b; L1;
V1
Interlabial sulcus pN2b Skin, LN
obturator
7mo SCC, pT1b
L1, V1
9 mo DoD
7; 47 y Papules,
plaques
pT1b Between clitoris
and urethra
(Fig 1, E, and
Fig 2, C and D)
pN0 (sn) Alive; 36 mo
8; 50 y Papules pT1b; L1 Clitoral hood pN2c (sn) Alive; 45 mo
9; 50 y Hypertrophic pT1b Periclitoral
(Fig 1, B)
pN0 (sn) DsD car
accident
11 mo
10; 55 y Papules pT1b Labium minus pN0 (sn) Alive; 12 mo
11; 56 y Papules and
plaques
pT1b; L1 Between clitoris
and urethra
pN2c Pelvic LN; skin 11 mo SCC pT1b
with pelvic
exenteration
11 mo SCC
pT1b
and pelvic
recurrence
Alive; 22 mo
12; 63 y Papules pT1b Between clitoris
and urethra
(Fig 1, F )
pN0 (sn) Alive; 108 mo
13; 64 y Hypertrophic pT1b Periclitoral pN0 12 mo SCC pT1b 11 mo SCC
pT1b
25 mo
d-VIN
7 mo SCC
pT1b
30 mo SCC
pT2 (m7)
95 mo DoD
14; 66y plaques pT1a inner side
labium minus
pN0 41 mo d-VIN (m) lost to
follow-up
after 44 mo
15; 66 y Atrophic
plaques
pT1a Between clitoris
and urethra
pN0 Alive; lost to
follow-up
after 31 mo
16; 66 y Papules pT1b Periclitoral pN1a (sn) Alive; 36 mo
17; 67 y Hypertrophic pT2; L1 Periclitoral pN1a Skin 18 mo SCC pT1b 7 mo SCC
pT1b
14 mo SCC
pT1b (m)
42 mo DoD
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18; 69 y Erosive pT2 Between urethra
and clitoris,
labium minus
pN0 (sn) 74 mo SCC pT1b Alive; 83 mo
19; 70 y Hypertrophic pT1b
(Fig 1, C )
Interlabial sulcus pN0 (sn) 55 mo d-VIN 7 mo SCC
pT1b
(Fig 1, I)
77 mo DoD
20; 71 y Erosive pT1b Between urethra
and clitoris
pN2b (sn) Lung 24 mo DoD
21; 71 y Erosive pT1b (m2) Bilateral labium
minus
pN2c Liver; pelvic
LN
Chemoradiation
and surgery
12 mo DoD
22; 72 y Papules
plaques
pT2 (m2) L1 Between urethra
and clitoris
pN1a Alive; 132 mo
23; 73 y Erosive pT1b Vestibulum,
hymenal ring
pN2b Vaginal mets
und pelvic
LN
10 mo SCC
pT2; L1
17 mo DoD
24; 74 y Erosive pT2 Between urethra
and clitoris
pN0 (sn) Skin Alive; lost to
follow-up
after 92 mo
25; 75 y Erosive pT2; L1; V1 Between urethra
and clitoris
pN1a 6 mo mons
pubis and
pelvic disease
(M1)
8 mo DoD
26; 76 y Papules pT1b Labium minus pN2b Alive; 43 mo
27; 77 y Papules pT1a Periclitoral pN0 (sn) 31 mo d-VIN 7 mo d-VIN
(Fig 2, E
and F)
12 mo
d-VIN
(Fig 2, G
and H)
8 mo SCC
pT1b
Alive; 69 mo
28; 68 y Erosive pT1b Labium minus pN1a Alive; 12 mo
29; 78 y Erosive pT1b Between clitoris
and urethra
pN0 32 mo SCC pT1a 4 mo SCC
pT1b (2)
48 mo DoD
30; 80 y Erosive pT2 Between clitoris
and urethra,
hymenal ring
pN1a 7 mo omentum
(M1)
8 mo DoD
31; 80 y Hypertrophic pT1b (m2) Periurethral,
periclitoral
(Fig 1, H )
pN0 (sn) 5 mo d-VIN Alive; 33 mo
32; 81 y Papule pT1b Labium minus pN0 108 mo SCC
pT1a, pN0 (sn)
11 mo d-VIN 5 mo SCC
pT1b
15 mo SCC
pT1b
5 mo SCC
pT1a (m2)
Alive; 151 mo
33; 81 y Erosive pT1a Inner labium
minus,
vestibulum
pN0 (sn) DsD pneumonia;
66 mo
34; 83 y Erosive pT2 Hymenal ring pN0 (sn) 42 mo DoD
35; 84 y Papules pT2 and
pT1b (m3)
Hymenal ring,
perineum
pN0 12 mo d-VIN 12 mo SCC
pT1b; pN1a
37 mo DoD
Continued
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702 Regauer, Reich, and Eberzhypertrophic plaques with increased skin markings
(lichenification) and varying amounts of hyperkera-
tosis (Fig 1, B, G, and H ). Five of 38 patients had a
solitary pT1a SCC (13%), 18 of 38 patients had a
solitary pT1b SCC (47%), 9 of 38 women presented
with a solitary pT2 SCC (24%) (Fig 1, A toG), and 6 of
38 women had multifocal SCCs at presentation (16%)
(Fig 1, H ). Sixteen of 38 (42%) women had inguinal
lymph node metastases at presentation. There was a
wide variation of vulvar architectural changes
reflecting the different disease stages of LP. In early
disease stages and all pT1a SCC, the vulvar anatomy
was not or only mildly altered, mainly perceived as
stiffening and mild or focal adhesion of labia minora
and the periclitoral mucosa (Fig 1, A, D, E, and F ).
Advanced LP stages were characterized by partial or
complete loss of normal vulvar architecture, eg, the
labia minora were partially or completely fused, the
clitoris was buried, and periclitoral tissues were
scarred (Fig 1, B and G to I ). Varying degrees of
stenosis of the vaginal introitus were documented in
18 women (Fig 1, G and H ). In some patients, it was
therefore difficult to determine the exact anatomic
location of the cancers. The primary SCCs were
located in modified mucosa of clitoral hood (n = 2)
(Fig 1, A), on the labium minus (n = 5), near the
clitoris (n = 8) (Fig 1, B and H ), and in the interlabial
sulcus (n = 3) (Fig 1, C ). SCCs was located in the
vestibulum in 20 patients. Thirteen of 20 vestibular
SCCs were located between clitoris and urethra
(Fig 1, D to F ), 4 of 20 SCCs were located in the
posterior vestibulum involving the hymen and peri-
neum (Fig 1,G), and 3 of 20 SCCs were located at the
vestibular border facing the inner side of labium
minus. All pT2 SCCs involved the entire vestibulum.
The multifocal SCCs involved the vestibulum, labia
minora, and periclitoral mucosa with LP separating
the cancers (Fig 1, H ). SCCs in hair-bearing vulva
were not identified.
Of 38 women, 27 women had no prior diagnoses
of LP or had not been in regular gynecologic or
dermatologic follow-up for their LP or been treated
according to standard protocols when they
presented with their SCC. Many patients reported a
rapid development of SCC, but it was documented
only in 4 women. Two women had a biopsy
specimen of a LP plaque between clitoris and urethra
revealing a d-VIN 4 and 5 months before a pT1a SCC
was excised. The third patient with advanced LP had
been in regular 6-month gynecologic control visits
for 3 years when she noted a hyperkeratotic plaque
5 months after the last uneventful gynecologic visit,
which was biopsied and diagnosed as SCC. The
resection, performed 6 weeks later, revealed a pT1b
SCC (patient 9) (Fig 1,B). She remained free of vulvar
J AM ACAD DERMATOL
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Regauer, Reich, and Eberz 703recurrence and metastases until she died in a car
accident 11 months later. The fourth woman was in
yearly follow-up for a hypertrophic LP when she
presented with a pT1b SCC 11 months after the last
uneventful control visit.
Treatment and clinical course of
LP-associated SCC
Treatment was primary chemoradiation in 2
patients, followed by subsequent surgical excision
in 1 of 2 patient. Surgical excision with clear margins
of at least 1 cm in 36women left residual lesions of LP
behind in all patients. All women underwent either
complete inguinal lymph adenectomy or sentinel
lymph node excision. In all, 21 of 38 (55%) women
had no metastases and 17 of 38 (45%) women had
regional LN metastases greater than 2 mm at
presentation. Distant metastases (skin, pelvic lymph
nodes, lung, liver) at presentation were present in 7
of 38 (18%) patients. The patient with primary
chemoradiation therapy without surgery developed
4 recurrences at the site of the original SCCs, which
were all resected. Fourteen of 36 (39%) women with
surgical treatment developed between 1 and 5 local
vulvar recurrent SCC (Fig 1, I, and Fig 2, E and G).
Five of 14 women (36%; 2 pT1b and 3 multifocal
SCC) had a single recurrence (4 of 5 within 5-12
months, 1 of 5 after 41 months). Nine of 14 women (1
pT1a, 4 pT1b, 2 pT2 SCC, and 2 multifocal SCC)
developed multiple recurrences. In all, 23 of 34
(68%) of all vulvar recurrent cancer and precursors
occurred within 5 to 12 months (Table I). Longer
disease-free survival was associated with wider
primary resections of SCC. Three of 38 patients
were lost to follow-up; 19 of 38 women are presently
alive with a mean follow-up of 57 months (range
12-151 months). Two of 38 women died of unrelated
causes without recurrent disease and 14 of 38 (37%)
women (7 pT1b, 5 pT2 SCC, 2multifocal SCC) died of
disease after a mean of 31 months (range 7-94
months) after initial diagnosis.
Histomorphologic characteristics of
LP-associated SCC
The SCCs were moderately differentiated, focally
keratinizing cancers, but nonkeratinizing areas were
common at the invasion front. Thirty of 38 SCCs had
active disease with a moderate to dense inflamma-
tory infiltrate (Fig 2, A to C and F ). Only 8 of 38
primary SCCs had no or scant lymphocytic infiltrates.
All SCCs, peritumoral intraepithelial precancerous
lesions, and precursor lesions before recurrent
SCC were devoid of HPV-DNA and p16ink4a over-
expression. Elongated rete ridges with basal atypia,
numerous mitoses, and premature squamatization inbasal and suprabasal cells with normal superficial
keratinization typical of d-VIN was identified
adjacent to the primary invasive SCC in 22 of 38
patients (Fig 2, E and F ). The remaining peritumoral
and recurrent precursors revealed atypical basaloid
differentiation (Fig 2, G and H ), or were flat or
hypertrophic verrucous proliferations with or
without hyperkeratosis. Nuclear p53 expression in
invasive tumor cells (Fig 2, C and D) and in d-VIN
was observed in 24 of 38 patients (67%).
DISCUSSION
To our knowledge, this is the largest series of
vulvar HPV-negative SCCs associated with LP. The
majority of SCCs were ulcerated large cancers. About
one third of LP-associated SCCs arose in erosive LP,
the remaining SCCs in papules and plaques of
nonerosive forms of LP. All SCCs were located
in nonhair-bearing vulvar mucosa, eg, vestibular
glycogenated mucosa and modified mucosa. The
vestibulum, in particular the glycogenated mucosa
between clitoris and urethra, was a typical location
of SCCs in our patient cohort. A group of gyneco-
logists has described a similar location for p16ink4a
and p53-negative vulvar SCCs in younger women22
and proposed a third type of vulvar cancer. The p53
negativity in immunohistochemical analysis and
inconsistent p53 staining in HPV-negative SCCs,
however, is widely recognized and these
cancers belong into the HPV-negative group of
vulvar cancers defined by the World Health
Organization.14 Although the authors did not
comment on presence or absence of dermatoses in
these patients, it is very likely that these cancers were
(possibly missed) cases of LP-associated SCCs. Both
clinical and histologic features of early and
nonerosive forms of LP in this area are extremely
subtle and often not recognized. The rarity of
anogenital LP may be another contributing factor
for inadequate recognition, particularly when LP is
not suspected especially, which is more common in
subspecialties not as familiar with the various
manifestations of LP as dermatologists. Recognition
of small lesions of LP lesions may require a vulvo-
scopic and colposcopic examination and are easier
to identify in a hairless (preoperative) vulva than in a
routine gynecologic practice setting. Obvious clini-
cal findings such as the erosive and hypertrophic
variants of LP were observed only in 50% of patients.
LP-associated SCCs are aggressive malignancies
with a high rate of regional lymph nodes metastases
at presentation and over 30% of disease-related
deaths, mainly within the first 1 to 3 years. We
observed a high rate of recurrent cancers in the
residual diseased skin, with 68% of all recurrences
Fig 1. Lichen planus (LP)-associated vulvar squamous cell carcinomas (SCCs). A, Ulcerated
pT1b SCC (arrow) on the clitoral hood of a 40-year-old woman (patient 2) with numerous skin-
colored plaques of LP (arrowheads) on both labia minora, which are small and stiff, and in the
right interlabial sulcus, and lichenification of periclitoral mucosa (arrowhead ). Note mild
architectural changes of posterior labial adhesion. B, Periclitoral invasive pT1b SCC (arrow)
with peritumoral erosion in a 52-year-old woman (patient 9) in advanced LP. The clitoris is
completely buried, and both labia minora are completely fused and reveal confluent plaques of
LP with increased skin markings (arrowhead). C, Primary pT1b SCC of a 70-year-old woman
(patient 19) arising in the interlabial sulcus in a hypertrophic LP. D, A pT1a SCC (arrow,
maximal invasion depth 0.4 mm) of a 39-year-old woman (patient 1) between clitoris and
urethra. Note the numerous plaques of LP on the clitoris, periclitoral tissues, and vestibulum
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Regauer, Reich, and Eberz 705occurring within 5 to 12 months. The high rate of
recurrent canceredespite complete removal of the
cancer with a minimum margin of 1 cmeis puzzling.
One possible explanation may be the trend towards
minimal surgery, which removes the cancer, but
leaves LP-affected skin and mucosa behind. It is
conceivable that a d-VIN was already present at time
of excision of the primary cancer, but not recognized
clinically as a precursor lesion or mistaken as a
plaque of LP. Another explanation may be that the
residual LP was not adequately treated, eg, poorly
controlled, suggesting that an active LP is a risk
factor for recurrent SCC. The fast development of
recurrent cancer supports indirectly that d-VIN is
a rapidly progressing precursor lesion. The
HPV-negative precursor lesions of d-VIN showed a
variety of atrophic and flat lesions, but also
verrucous and exophytic proliferations, and
basaloid differentiation as reported before in
lichen sclerosuseassociated cancers.23-25 Criteria
for d-VIN are often subtle in daily surgical practice
with hematoxylin-eosinestained sections. Lack of
p16ink4a overexpression and proof of HPV negativity
are helpful for a correct etiologic identification. This
distinction is essential because d-VIN with a fast
progression to SCC needs immediate treatment and
cannot be treated expectantly or with topical
immune modulators for several weeks such as
HPV-induced precursors. Furthermore, our data
suggest that active LP in general is at risk for
malignant transformation, because the majority of
our patients received no standardized treatment for
their LP before development of SCC. The aim should
be a reduction of lymphocytes, thus reducing tissue
destruction and possibly preventing malignant
transformation.
In conclusion, LP-associated SCCs are HPV-
negative cancers located in glycogenated and(arrowhead). E, A pT1b SCC (arrow, maximal in
clitoris and urethra in a 47-year-old-woman. Mu
around the clitoris, clitoral hood, and inner side
F, Ulcerated pT1b SCC located between urethra an
with numerous individual plaques in periclitora
stiffening of labia minora and labial fusion in the
pT1b SCC (arrow) in the posterior vestibulum
woman (patient 37). Note the numerous confluen
the extensively scarred vulva with buried clitoris an
Blue dye is from injection of radioactive tra
identification. H, Multifocal pT1b SCC (arrows)
changes including complete loss of labia minora
vaginal introitus of a 80-year-old woman (patient 3
LP. I, Second recurrent cancer of patient 19 is an u
vestibulum. Scar of excision of prior primary SCC (
vestibulum (arrowhead). Architectural changes
stenosis of vaginal introitus.modified vulvar mucosa, but not in hair-bearing
vulvar skin. LP-associated SCCs arise via the
precursor d-VIN. The aggressive SCCs have a high
rate of LN metastases at initial presentation and 30%
disease-related deaths. Almost 40% of patients had
recurrent cancer in the residual diseased LP, mostly
within the first 12 months postoperatively, which
calls for close oncologic follow-up. We further
propose that women with LP with or without a prior
vulvar SCC need regular follow-up and appropriate
treatment for control of their LP.
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